IRWD Live signaler | Maksimer profitt med Getagraph.com

KJøP 114281 min ago

@ $15.52

Utstedt: 14 feb 2024 @ 19:33

Avkastning: -47.68%

Forrige signal: feb 13 - 20:42

Forrige signal: Selg

Avkastning: 2.37 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	1.82M
Gjennomsnittsvolum	4.54M
Markedsverdi	1.29B
EPS	$0 ( 2024-05-02 )
Neste inntjeningsdato	( $0.190 ) 2024-06-18
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.260
ATR14	$0.00700 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Denner Alexander J	Buy	1 662	Class A Common Stock
2024-03-08	John Minardo	Buy	32 752	Class A Common Stock
2024-03-08	John Minardo	Sell	32 752	Performance-based Restricted Stock Unit
2024-03-08	Emany Sravan Kumar	Buy	37 120	Class A Common Stock
2024-03-08	Emany Sravan Kumar	Sell	37 120	Performance-based Restricted Stock Unit

INSIDER POWER
45.55
Last 100 transactions
Buy: 2 835 189 \| Sell: 1 035 601

Volum Korrelasjon

Lang: -0.40 (neutral)

Kort: -0.38 (neutral)

Signal:(40.922) Neutral

Ironwood Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
LUNG	0.956
NERV	0.942
GASS	0.905
BNIXU	0.902
IBRX	0.896
BNTX	0.888
RAPT	0.886
DBX	0.884
CREG	0.883
GOOD	0.883

10 Mest negative korrelasjoner
BZFD	-0.953
SYKE	-0.943
APOP	-0.924
KTOS	-0.921
PPD	-0.91
BLU	-0.91
SSIC	-0.909
BNIX	-0.905
TYHT	-0.904
ACVA	-0.903

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Ironwood Pharmaceuticals Korrelasjon - Valuta/Råvare

0.57
( weak )

0.30
( neutral )

0.00
( neutral )

-0.53
( weak negative )

0.56
( weak )

Ironwood Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$442.74M
Bruttogevinst:	$441.16M (99.64 %)
EPS:	$-6.45

FY	2023
Omsetning:	$442.74M
Bruttogevinst:	$441.16M (99.64 %)
EPS:	$-6.45

FY	2022
Omsetning:	$410.60M
Bruttogevinst:	$409.18M (99.65 %)
EPS:	$1.130

FY	2021
Omsetning:	$413.75M
Bruttogevinst:	$413.75M (100.00 %)
EPS:	$3.26

Financial Reports:

No articles found.

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.